In cancer, recent studies suggest that CCR2 is expressed not only in immune cells, such as monocytes and T cells but also in most types of solid and blood cancer cells, such as breast and renal carcinoma [8], which expands the applicability of future CCR2 degraders to a large variety of relevant cell lines and disease models. Here, CCR2 is linked to renal carcinoma.